Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes

Recombinant activated factor VII (rFVIIa) is an effective treatment of the haemophilia patient with inhibitors and acquired haemophilia. However, on account of its relatively short half‐life (HL), achieving therapeutic efficacy with FVIIa requires repeated injections. The development of a long‐actin...

Ausführliche Beschreibung